Abbreviations
- ACT:
-
Adoptive cell therapy
- APC:
-
Antigen-presenting cells
- AS:
-
Adjuvant system
- CIK:
-
Cytokine-induced killer
- COA:
-
Colon antigen
- CRC:
-
Colorectal cancer
- CSC:
-
Cancer stem cells
- CTC:
-
Circulating tumor cells
- CTL:
-
Cytotoxic T lymphocytes
- CTLA-4:
-
Cytotoxic T lymphocyte-associated antigen-4
- CTX:
-
Cyclophosphamide
- DC:
-
Dendritic cells
- DXR:
-
Doxorubicin
- HDI:
-
High-dose interferon-alpha-2b
- IDO:
-
Indoleamine 2,3-dioxygenase
- IFN:
-
Interferon
- IL:
-
Interleukin
- mAb:
-
Monoclonal antibody
- MM:
-
Metastatic melanoma
- NB:
-
Neuroblastoma
- NGR:
-
Asn-Gly-Arg
- NHL:
-
Non-Hodgkin lymphoma
- NK:
-
Natural killer
- PC:
-
Pancreatic cancer
- PTPRK:
-
Protein tyrosine phosphatase receptor kappa
- TAA:
-
Tumor-associated antigen
- TERT:
-
Telomerase reverse transcriptase
- TRAMP:
-
Transgenic adenocarcinoma mouse prostate
- Tregs:
-
Regulatory T cells
Acknowledgments
This work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro and Alleanza Contro il Cancro.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The collaborators of NIBIT are given in the appendix.
Appendix: Collaborators
Appendix: Collaborators
Paola Allavena, Istituto Clinico Humanitas IRCCS, Rozzano (MI), Italy;
Andrea Anichini, National Cancer Institute, Milan, Italy;
Matteo Bellone, San Raffaele Scientific Institute, Milan, Italy;
Vincenzo Bronte, Istituto Oncologico Veneto, Padua, Italy;
Luana Calabrò, University Hospital of Siena, Siena, Italy;
Chiara Camisaschi, National Cancer Institute, Milan, Italy;
Chiara Castelli, National Cancer Institute, Milan, Italy;
Angelo Corti, San Raffaele Scientific Institute, Milan, Italy;
Marco Danova, San Matteo Hospital, Pavia, Italy;
Paolo Dellabona, San Raffaele Scientific Institute, Milan, Italy;
Anna Maria Di Giacomo, University Hospital of Siena, Siena, Italy;
Massimo Di Nicola, National Cancer Institute, Milan, Italy;
Guido Ferlazzo, University of Messina, Messina, Italy;
Giusy Gentilcore, National Cancer Institute, Naples, Italy;
Leonardo Giovannoni, Philogen, Siena, Italy;
Patrick Hwu, M.D. Anderson Cancer Center, Houston, USA;
Frederic Lehmann, GlaxoSmithKline, Rixensart, Belgium;
Cristina Maccalli, San Raffaele Scientific Institute, Milan, Italy;
Ignacio Melero, University of Navarra, Pamplona, Spain;
Vladia Monsurrò, University of Verona, Verona, Italy;
Daniela Montagna, Fondazione IRCCS, Policlinico San Matteo, University of Pavia, Pavia, Italy;
Federica Moschella, Istituto Superiore di Sanità, Rome, Italy;
Mirco Ponzoni, Gaslini Children’s Hospital, Genoa, Italy;
Maria Pia Protti, San Raffaele Scientific Institute, Milan, Italy;
Paolo Puccetti, University of Perugia, Perugia, Italy;
Dario Sangiolo, Institute for Cancer Research and Treatment, Turin, Italy;
Gerold Schuler, University Hospital of Erlangen, Erlangen, Germany.
Rights and permissions
About this article
Cite this article
Maio, M., Nicolay, H.J.M., Ascierto, P.A. et al. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009. Cancer Immunol Immunother 59, 1895–1901 (2010). https://doi.org/10.1007/s00262-010-0832-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-010-0832-2